Cardiovascular Innovation Forum at VBEF 2026: A Full-Chain Ecosystem Gathering in Suzhou This May
Cardiovascular disease is the leading killer threatening global human health and longevity, with a mortality rate of up to 5% among patients aged 65 and older. In China, the number of individuals affected by cardiovascular diseases exceeds 300 million. As the prevalence of chronic heart conditions continues to rise, the cardiovascular device sector remains highly dynamic.
In niche segments, pulsed field ablation (PFA), as the “next-generation ablation technology,” can eliminate diseased tissue while ensuring no damage to surrounding healthy tissue. Domestic products have already received regulatory approval, and Chinese companies are accelerating their catch-up efforts. The valve intervention market holds promising prospects; with increasing clinical penetration, domestic firms at the forefront of innovation are poised to secure a place among global giants in valve device manufacturing. The introduction of pulsed field ablation marks the dawn of a new era in cardiac electrophysiology and is reshaping standards of care. Domestically produced renal denervation (RDN) products are competing alongside imported devices, jointly exploring new opportunities in the device-based treatment of hypertension.
On the policy front, the Beijing Municipal Healthcare Security Administration has included implantable left ventricular assist device (LVAD) implantation in the Class A reimbursement coverage of Beijing’s basic medical insurance. The National Healthcare Security Administration has explicitly stated that it will prioritize guiding the inclusion of seven major categories of high-value medical consumables, including cardiac interventional materials, into centralized volume-based procurement programs. The rollout of these favorable policies provides strong support for industry development.
Based on this,VCBeat to Host “Cardiovascular Disease Industry-Research Innovation Forum” at the VBEF Top 100 Future Healthcare and Pharma Exhibition on May 9–10, to promote the in-depth development of cardiovascular devices in China. The forum will feature discussions on four key aspects: meeting clinical needs, commercialization pathways from a capital perspective, technological innovation by domestic manufacturers, and regulatory approval. It aims to provide a high-end platform for exchange and collaboration among experts, scholars, device manufacturers, and investment institutions deeply engaged in the field of cardiovascular diseases, thereby offering strong support and impetus for technological innovation and coordinated development across the cardiovascular device industry chain.
From the perspective of hospital presidents, this analysis deeply examines the precise alignment between cardiovascular device R&D and clinical pain points. Supported by data from the White Paper on Cardiac Electrophysiology Ablation, it reveals directions for breakthroughs in domestically produced technologies, forming a closed-loop logic between “demand-side” and “R&D-side.”
Focusing on the Localization of Pulsed Field Ablation (PFA) Technology: Exploring Its Technical Advantages and Market Prospects in Replacing Traditional Radiofrequency/Cryoablation, and Demonstrating the Iterative Upgrade Trend of Precise and Efficient Diagnostic and Therapeutic Technologies Through Case Studies of Companies Such as Puchuang Medical
By integrating key stages such as CRO-accelerated regulatory approval, capital-driven solutions to commercialization bottlenecks, and clinical validation, this approach fosters collaboration among medical, academic, research, and industrial stakeholders through roundtable dialogues. It aims to build an industry empowerment system encompassing “R&D, compliant implementation, and market expansion,” thereby advancing the maturity of the innovation ecosystem for cardiovascular devices.
May 9, 14:00-17:00
(The following is a tentative schedule; the actual arrangement shall be subject to on-site conditions.)
14：00-14：20
“How Can Cardiovascular Device Innovation Better Align with Clinical Needs?” (Proposed)
Wang Yan | President (Designate) of Xiamen University Affiliated Cardiovascular Hospital
14：20-14：40
“How Cardiovascular Device Companies Can Crack the Commercialization Challenge” (Proposed)
Investment Institutions
14：40-15：00
“White Paper on Cardiac Electrophysiology Ablation” Released
Senior Researcher, VBInsight
15：00-15：20
《Major Players Increase Investment, Domestic Innovations Rise: PFA Set to Dominate Cardiac Ablation Technology in the Next Decade (Draft)》
Representative Domestic PFA Enterprises
15：20-15：40
"Technological Innovation: Making Healthcare More Precise and Efficient"
Peng Huiqun | Founder and CEO of Puchuang Medical
15：40-16：00
How CROs Empower the Rapid Approval of Domestically Produced Innovative Cardiovascular Devices (Proposed)
Representative of a Medical Device CRO Company
16：00-16：40
Roundtable Discussion: The Path of Transformation, Opportunities, and Challenges in Cardiovascular Devices (Proposed)
Representatives from Various Sectors of the Cardiovascular Disease Community
More speaker topics and guests are being confirmed!
Event Agenda:
1. Repost this post to your WeChat Moments (set visibility to public, no group restrictions);
2. Retain the tweet for 1 hour and accumulate 18 likes on WeChat Moments;
3. Add the customer service WeChat account and send the screenshot;
4. Receive a complimentary conference ticket valued at 399 yuan;
Event Agenda:
1. Your company is an upstream or downstream enterprise in the cardiovascular field;
2. Add our customer service on WeChat and provide your personal business card;
3. Obtain a free admission ticket (valued at 399 yuan);
(Choose one of two promotional offers)
Scan the QR code belowParticipate in the promotional event for the "Cardiovascular Disease R&D Innovation Forum,"Contact the Organizing Committee to obtain tickets!
